Jad Kebbe, MD
Pulmonary Disease · Oklahoma City, OKNPI 1487968418
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by United Therapeutics Corporation at 37.2% of the total. Reporting peaked in 2024 at $1,961 and has fallen 55.8% since, to $866 in 2025.
Across 95 payments — averaging $62.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$2K
- Boehringer Ingelheim International GmbH$2K
- Vertex$450
- AbbVie$218
- Boehringer Ingelheim$216
- Gilead$199
- plus $745 from 14 others
Across 210 payments — averaging $6977.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$504K
- Boehringer Ingelheim$371K
- E.r. Squibb & Sons, L.L.C.$231K
- Genentech, Inc.$209K
- CSL Behring$90K
- Boehringer Ingelheim International GmbH$60K
What the payments were for
- Consulting fees$4508%
- Speaking & faculty fees$1,88032%
- Travel & lodging$1,17120%
- Food & beverage$2,40741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 20 | $2,200 |
| Boehringer Ingelheim International GmbH | 1 | $1,880 |
| Vertex | 1 | $450 |
| AbbVie | 9 | $218 |
| Boehringer Ingelheim | 10 | $216 |
| Gilead | 9 | $199 |
| Genentech USA, Inc. | 9 | $153 |
| GSK | 8 | $136 |
| Sunovion Pharmaceuticals Inc. | 6 | $128 |
| Inogen, Inc. | 8 | $107 |
| Novartis | 2 | $44 |
| Merck | 3 | $42 |
| AstraZeneca | 2 | $23 |
| Chiesi USA, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Amgen | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,907 in reported general payments places this provider in the 70th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 313 | $3,944,960 |
| EsbrietPirfenidone | 20 | $202,135 |
| XolairOmalizumab | 51 | $174,952 |
| Pirfenidone | 67 | $104,002 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $87,927 |
| NucalaMepolizumab | 20 | $79,123 |
| Actemra ActpenTocilizumab | 17 | $77,465 |
| TezspireTezepelumab-Ekko | 11 | $48,579 |
| JardianceEmpagliflozin | 36 | $26,941 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $22,372 |
| Mycophenolate Mofetil | 121 | $20,578 |
| EliquisApixaban | 19 | $18,098 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $15,925 |
| Spiriva RespimatTiotropium Bromide | 14 | $13,229 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Spiriva Respimat, Stiolto Respimat | $216 | $3,997,376389 claims |
| Genentech USA, Inc.Esbriet | $153 | $202,13520 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $136 | $199,530200 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Farxiga | $23 | $75,86745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.